In line with the ESC mission, newly presented content is made available to all for a limited time (4 months for ESC Congress, 3 months for other events). ESC Professional Members, Association Members (Ivory & above) benefit from year-round access to all the resources from their respective Association, and to all content from previous years. Fellows of the ESC (FESC), and Professionals in training or under 40 years old, who subscribed to a Young Combined Membership package benefit from access to all ESC 365 content from all events, all editions, all year long. Find out more about ESC Memberships here.
Five-year results of endovascular treatment of patients with left main coronary arteries bifurcation lesions
Aims: To evaluate long-term results of endovascular treatment in patients with bifurcation left main coronary artery diseases.
Methods and results: 284 patients were enrolled in the study, which randomized into 2 groups: group I (n=132) were included patients with true bifurcation lesions, which implanted Everolimus-eluting stents, and group II (n=152) – were non-bifurcations, which implanted Paclitaxel-eluting stents. The both groups were additionally randomized into 2 subgroups: subgroup IA, IIA (n=66 in each subgroup) - included patients, who underwent 1-stent bifurcation strategy and subgroup IB, IIB (n=76 in each subgroup) - who underwent 2-stent strategy (Culotte and Crush/Mini-Crush). For all patients, who underwent 2 stents in bifurcation, were performing subanalysis, depending on the technique of bifurcation stenting. Inclusion criteria: true and non-bifurcation lesions of left main coronary artery + 1 or 2 vessel diseases (SYNTAX score <32); stenosis of the left main coronary artery, confirmed by FFR<0.8; stable angina classes II-IV (CCS). Primary endpoints: MACE. Secondary endpoints: restenosis and late stent thrombosis according to digital angiography and IVUS.
In group I, who implanted Everolimus-eluting stents, MACE was 5.3%. In group II, who implanted Paclitaxel-eluting stents, frequency of MACE was 7.2% (p=0,003). The ratio of restenosis in bifurcation area, according digitalangiographyin both groups was 6.8 and 9.8% respectively (p=0.0024). Ratio of TLR in both groups amounted 4.5 and 6.5% respectively (p=0.004). IVUS-results in subgroup IA and IIA:the average residual lumen area in the proximal part of LMCA was 7,02+0,03 and 7.55+0.02 mm2 (p>0.05), at the ostia of the LCx - 5,0+0,12 and 5,88+0,01 mm2 (p=0.02), at the ostia of the LAD - 6,13+0,03 and 6.88+0,04 mm2 (p=0.03). The MACE in subgroup IA and IIA was 9.1 and 1.5% respectively (p<0.001). IVUS-results in subgroup IIA and IIB:the average residual lumen area in the proximal part of LMCA was 7,22+0,03 and 7.55+0.02 mm2 (p>0.05), at the ostia of the LCx - 5,0+0,12 and 5,64+0,01 mm2 (p=0.024), at the ostia of the LAD - 6,0+0,03 and 6.84+0,04 mm2 (p=0.027). The MACE in subgroup IB and IIB was 10.5 and 3.9% respectively (p<0.001).142 patients in the study were implanted two stents at the bifurcation. The distribution of patients according to the stenting technique was equivalent, with 70 in each group. The MACE in Culotte and Crush/Mini-Crushgroups was 0 and 5.7% respectively (p<0.001). Defined stent thrombosis were no significant difference in both groups.
Conclusions: Everolimus-eluting stents associated with higher efficacy and safety in bifurcation stenting of left main coronary artery, compared with Paclitaxel-eluting stents. Culotte-technique of LMCA bifurcation stenting shows better long-term results, as compared to Crush/Mini-Crush-technique. Two-stent strategy can be the preferred for endovascular treatment of true left main coronary artery bifurcation lesions.
In line with the ESC mission, newly presented content is made available to all for a limited time (4 months for ESC Congress, 3 months for other events). ESC Professional Members, Association Members (Ivory & above) benefit from year-round access to all the resources from their respective Association, and to all content from previous years. Fellows of the ESC (FESC), and Professionals in training or under 40 years old, who subscribed to a Young Combined Membership package benefit from access to all ESC 365 content from all events, all editions, all year long. Find out more about ESC Memberships here.
ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.
Our mission: To reduce the burden of cardiovascular disease
